全文获取类型
收费全文 | 2204篇 |
免费 | 123篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 80篇 |
妇产科学 | 34篇 |
基础医学 | 215篇 |
口腔科学 | 55篇 |
临床医学 | 174篇 |
内科学 | 789篇 |
皮肤病学 | 18篇 |
神经病学 | 126篇 |
特种医学 | 61篇 |
外科学 | 205篇 |
综合类 | 51篇 |
一般理论 | 1篇 |
预防医学 | 89篇 |
眼科学 | 64篇 |
药学 | 197篇 |
中国医学 | 5篇 |
肿瘤学 | 131篇 |
出版年
2023年 | 23篇 |
2022年 | 11篇 |
2021年 | 103篇 |
2020年 | 62篇 |
2019年 | 118篇 |
2018年 | 109篇 |
2017年 | 63篇 |
2016年 | 86篇 |
2015年 | 63篇 |
2014年 | 94篇 |
2013年 | 93篇 |
2012年 | 149篇 |
2011年 | 153篇 |
2010年 | 80篇 |
2009年 | 75篇 |
2008年 | 130篇 |
2007年 | 110篇 |
2006年 | 103篇 |
2005年 | 81篇 |
2004年 | 83篇 |
2003年 | 58篇 |
2002年 | 41篇 |
2001年 | 39篇 |
2000年 | 31篇 |
1999年 | 21篇 |
1998年 | 18篇 |
1997年 | 9篇 |
1996年 | 8篇 |
1995年 | 8篇 |
1994年 | 11篇 |
1993年 | 7篇 |
1992年 | 23篇 |
1991年 | 23篇 |
1990年 | 22篇 |
1989年 | 23篇 |
1988年 | 20篇 |
1987年 | 12篇 |
1986年 | 11篇 |
1985年 | 11篇 |
1984年 | 13篇 |
1983年 | 14篇 |
1981年 | 14篇 |
1979年 | 13篇 |
1978年 | 6篇 |
1975年 | 6篇 |
1974年 | 8篇 |
1973年 | 11篇 |
1972年 | 7篇 |
1969年 | 10篇 |
1966年 | 8篇 |
排序方式: 共有2331条查询结果,搜索用时 15 毫秒
111.
112.
The platelet has assumed an increasingly important role in cardiovascular medicine as our understanding of the pathophysiology of acute coronary syndromes (ACS) has evolved. Plaque rupture, platelet aggregation, and thrombus formation occur as a result of complex interaction between the platelet, the endothelium, and various inflammatory cells and circulating proteins. Aspirin continues to form the foundation of any anti-ischemic regimen, but cardiologists have long recognized the need for newer, more potent antiplatelet agents. Glycoprotein IIb/IIIa receptor antagonists and thienopryidines have been developed over the past decade and now serve as powerful complements to aspirin in the prevention and treatment of coronary events. The paper will begin with a review of aspirin as well as a discussion of the concept of aspirin resistance. The rapidly expanding body of knowledge supporting the use of glycoprotein IIb/IIIa receptor blockers and thienopyridines will then be addressed, with an emphasis on reconciling recent controversies in the literature. Future advances in the treatment of coronary artery disease will likely occur as we further refine the role of these established antiplatelet drugs and develop agents that bind to novel targets in the thrombotic cascade. 相似文献
113.
114.
Myelin regeneration is indispensably important for patients suffering from several central nervous system (CNS) disorders such as multiple sclerosis (MS) and spinal cord injury (SCI), because it is not only essential for restoring neurophysiology, but also protects denuded axons for secondary degeneration. Understanding the cellular and molecular mechanisms underlying remyelination is critical for the development of remyelination-specific therapeutic approaches. As remyelination shares certain common mechanisms with developmental myelination, knowledge from study of developmental myelination contributes greatly to emerging myelin regeneration therapies, best evidenced as the recently developed human anti-Nogo receptor interacting protein-1 (LINGO-1) monoclonal antibodies to treat MS patients in clinical trials. 相似文献
115.
Choice of Vein‐Harvest Technique for Coronary Artery Bypass Grafting: Rationale and Design of the REGROUP Trial 下载免费PDF全文
Marco A. Zenati MD MSc J. Michael Gaziano MD MPH Joseph F. Collins ScD Kousick Biswas PhD Jennifer M. Gabany MSN CRNP CCRC Jacquelyn A. Quin MD MPH Jerene M. Bitondo PA‐C Faisal G. Bakaeen MD Rosemary F. Kelly MD A. Laurie Shroyer PhD Deepak L. Bhatt MD MPH 《Clinical cardiology》2014,37(6):325-330
The Randomized Endo‐vein Graft Prospective (REGROUP) trial ( ClinicalTrials.gov NCT01850082) is a randomized, intent‐to‐treat, 2‐arm, parallel‐design, multicenter study funded by the Cooperative Studies Program (CSP No. 588) of the US Department of Veterans Affairs. Cardiac surgeons at 16 Veterans Affairs (VA) medical centers with technical expertise in performing both endoscopic vein harvesting (EVH) and open vein harvesting (OVH) were recruited as the REGROUP surgeon participants. Subjects requiring elective or urgent coronary artery bypass grafting using cardiopulmonary bypass with use of ≥1 saphenous vein graft will be screened for enrollment using pre‐established inclusion/exclusion criteria. Enrolled subjects (planned N = 1150) will be randomized to 1 of the 2 arms (EVH or OVH) after an experienced vein harvester has been assigned. The primary outcomes measure is the rate of major adverse cardiac events (MACE), including death, myocardial infarction, or revascularization. Subject assessments will be performed at multiple times, including at baseline, intraoperatively, postoperatively, and at discharge (or 30 days after surgery, if still hospitalized). Assessment of leg‐wound complications will be completed at 6 weeks after surgery. Telephone follow‐ups will occur at 3‐month intervals after surgery until the participating sites are decommissioned after the trial's completion (approximately 4.5 years after the full study startup). To assess long‐term outcomes, centralized follow‐up of MACE for 2 additional years will be centrally performed using VA and non‐VA clinical and administrative databases. The primary MACE outcome will be compared between the 2 arms, EVH and OVH, at the end of the trial duration. 相似文献
116.
117.
Jacqueline S. Garcia Shruti Bhatt Geoffrey Fell Adam S. Sperling Michael Burgess Hasmik Keshishian Binyam Yilma Andrew Brunner Donna Neuberg Steven A. Carr Benjamin L. Ebert Karen Ballen Richard M. Stone Daniel J. DeAngelo Bruno C. Medeiros Anthony Letai 《American journal of hematology》2020,95(3):245-250
Most patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) do not benefit from current re-induction or approved targeted therapies. In the absence of targetable genetic mutations, there is minimal guidance on optimal treatment selection particularly in the R/R setting highlighting an unmet need for clinically useful functional biomarkers. Blood and bone marrow samples from patients treated on two clinical trials were used to test the combination of lenalidomide (LEN) and MEC (mitoxantrone, etoposide, and cytarabine) chemotherapy in R/R AML patients. The bone marrow samples were available to test the clinical utility of the mitochondrial apoptotic BH3 and dynamic BH3 profiling (DBP) assays in predicting response, as there was no clear genetic biomarker identifying responders. To test whether LEN-induced mitochondrial priming predicted clinical response to LEN-MEC therapy, we performed DBP on patient myeloblasts. We found that short-term ex vivo treatment with lenalidomide discriminated clinical responders from non-responders based on drug-induced change in priming (delta priming). Using paired patient samples collected before and after clinical LEN treatment (prior to MEC dosing), we confirmed LEN-induced increased apoptotic priming in vivo, suggesting LEN enhanced vulnerability of myeloblasts to cytotoxic MEC chemotherapy. This is the first study demonstrating the potential role of DBP in predicting clinical response to a combination regimen. Our findings demonstrate that functional properties of relapsed AML can identify active therapies. 相似文献
118.
Journal of Thrombosis and Thrombolysis - Patients with atrial fibrillation who undergo percutaneous coronary intervention are at increased risk for both coronary and cerebral thrombotic events. As... 相似文献
119.
Radhakrishnan Mahesh Arghya Kusum Dhar Ankur Jindal Shvetank Bhatt 《Chemical biology & drug design》2014,83(5):583-591
A series of novel 1,8‐naphthyridine‐3‐carboxamides as 5‐HT3 receptor antagonists were synthesized with an intention to explore the antidepressant activity of these compounds. The title carboxamides were designed using ligand‐based approach keeping in consideration the structural requirement of the pharmacophore of 5‐HT3 receptor antagonists. The compounds were synthesized using appropriate synthetic route from the starting material nicotinamide. 5‐HT3 receptor antagonism of all the compounds, which was denoted in the form of pA2 value, was determined in longitudinal muscle myenteric plexus preparation from guinea‐pig ileum against 5‐HT3 agonist, 2‐methyl‐5‐HT. Compound 8g (2‐methoxy‐1, 8‐naphthyridin‐3‐yl) (2‐methoxy phenyl piperazine‐1‐yl) methanone was identified as the most active compound, which expressed a pA2 value of 7.67. The antidepressant activity of all the compounds was examined in mice model of forced swim test (FST); importantly, none of the compounds was found to cause any significant changes in the locomotor activity of mice at the tested dose levels. In FST, the compounds with considerably higher pA2 value exhibited promising antidepressant‐like activity, whereas compounds with lower pA2 value did not show antidepressant‐like activity as compared to the control group. 相似文献
120.
Bisphosphonates are inhibitors of osteoclastic bone resorption with therapeutic benefit in a variety of bone disorders in both adults and children. While these agents have been routinely used in adults for the past three decades, their more recent introduction into paediatric medicine means there is a paucity of data on long‐term safety and effects on dental development. There is uncertainty regarding the dental management of children treated with bisphosphonates, particularly when invasive dental procedures, such as extractions and oral surgical procedures, are required. There are limited data with which to make recommendations about the dental management of patients treated with bisphosphonates, and there are no published recommendations that specifically address paediatric patients. This paper aims to outline paediatric uses and adverse effects of bisphosphonates and present recommendations on the dental management of children receiving bisphosphonates. 相似文献